Cardalis- when to utilize RAAS suppression and why

It has been over 2 and 1/2 years since CARDALIS ® was FDA-approved for dogs with
symptomatic chronic degenerative valve disease. The combination of Benazepril and
Spironolactone in CARDALIS™ provides a unique combination of active ingredients to block
the effects of the RAAS cascade. These active ingredients are recommended by the ACVIM to
treat CHF at the onset of signs.